BRAIN Biotech AG has announced that current Chief Financial Officer Lukas Linnig is stepping down as CFO to lead Akribion Genomics, the newly established brand for the highly promising genome editing platform technology of BRAIN Group. Michael Schneiders, currently Head of Investor Relations & Sustainability, will be appointed as the new Chief Financial Officer of BRAIN Biotech AG.
Michael Schneiders has joined the company in May 2020 after more than twenty years in investment banking. He has also been involved in the initial public offering of BRAIN. The personnel changes in the executive management board of BRAIN Biotech AG will become effective as of October 1st, 2022. Linnig will be joined at Akribion Genomics by Dr. Michael Krohn, currently Head R&D BRAIN Biotech. Linnig and Krohn will jointly lead the activities under the brand name to fully capitalize on the great promise that genome editing represents to BRAIN and its customers. It is BRAIN’s stated intention to establish a separate legal entity for Akribion in the next year and to attract significant external growth funding for this venture.
Adriaan Moelker, CEO of BRAIN Biotech AG, says: “Lukas Linnig and Michael Krohn have been essential in leading our genome editing activities over the last years, driven by the great scientific progress made by the R&D team. It is only logical that they will now become the appointed leaders to drive Akribion Genomics towards its stated goals. Michael Krohn will assume his leadership role as soon as his successor takes over the R&D leadership at BRAIN. I am also looking forward to working together with Michael Schneiders on the executive board of BRAIN Biotech AG. Michael has proven IR, financial and business development skills and a well-established capital market track record.”
Dr. Georg Kellinghusen, Chairman of the Supervisory Board of BRAIN Biotech AG, says: "It is a very strong sign of confidence in the business potential of Akribion Genomics that the envisaged spin-out will be led by the high caliber team of Lukas Linnig and Dr. Michael Krohn. I am also happy that we have been able to capitalize on our internal succession planning with Michael Schneiders as the designated CFO of BRAIN Biotech."
Lukas Linnig states: “It has been a great honor for me to serve BRAIN as its CFO. Leading Akribion, I will be focusing my attention on accelerating one of BRAIN’s most important value drivers with transformational potential. I am thrilled to take on this challenge of building a successful business in the genome editing market under the Akribion Genomics brand.”
Dr. Michael Krohn, adds: “I am convinced about the potential of our proprietary genome editing technology, especially since our unique mode of action enables us to offer a very valuable addition to the existing genome editing toolsets.”